【摘要】 目的探讨50/500μg与50/250μg舒利迭治疗慢性阻塞性肺疾病(COPD)的效果。方法 60例重度慢性阻塞性肺疾病稳定期患者作为观察对象,随机分为A组和B组,每组30例,两组患者均给予茶碱缓释片0.2 g/次,2次/d,氨溴索片30 mg/次,3次/d。A组患者给予50/250μg舒利迭治疗,B组患者则给予50/500μg舒利迭治疗,比较两组患者肺功能改善情况和药物不良反应发生情况。结果治疗3个月后,B组患者用力肺活量、一秒用力呼气容积、峰值呼气流速、一秒用力呼气容积/用力肺活量显著优于A组,差异有统计学意义(P<0.05),与A组比较,B组患者药物不良反应未见明显增加,两组比较差异无统计学意义(P>0.05)。结论 50/500μg舒利迭治疗慢性阻塞性肺疾病临床疗效确切,优于50/250μg舒利迭治疗,具有安全高效和不良反应少等特点,值得临床推广。更多还原

【Abstract】 Objective To investigate the effect of 50/500 μg and 50/250 μg of Seretide in the treatment of chronic obstructive pulmonary disease(COPD). Methods A total of 60 patients with chronic obstructive pulmonary disease were taken as the observation subjects, and they were randomly divided into group A and group B with 30 cases in each group. Both groups received theophylline sustained release tablet by 0.2 g/time for 2 times/d, and ambroxol tablet by 30 mg/time for 3 times/d. The group A was given 50/250 μg of Seretide for treatment, while group B received 50/500 μg of Seretide for treatment. Comparisons were made on pulmonary function improvement condition and drug adverse reactions between the two groups. Results After 3 months of treatment, the group B had better forced vital capacity, forced expiratory volume in one second, peak expiratory flow rate, forced expiratory volume in one second/forced vital capacity than the group A, and the difference had statistical significance(P<0.05). Compared with group A, group B had no increased drug adverse reactions, and the difference had statistical significance(P>0.05). Conclusion 50/500 μg of Seretide provides precise effect in the treatment of chronic obstructive pulmonary disease better than 50/250 μg. This method has advantages of safe, effective, and few adverse reactions, and it is worthy of clinical promotion.更多还原